Literature DB >> 19789340

Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.

Bojie Dai1, X Frank Zhao, Patrick Hagner, Paul Shapiro, Krystyna Mazan-Mamczarz, Shuchun Zhao, Yasodha Natkunam, Ronald B Gartenhaus.   

Abstract

The MCT-1 oncogene was originally identified from lymphoma cell lines. Herein we establish that MCT-1 is highly expressed in 85% of human diffuse large B-cell lymphomas (DLBCL) and that knocking down MCT-1 by a specific short hairpin RNA in DLBCL cells induces apoptosis, supporting a critical role for MCT-1 in DLBCL cell survival. However, the mechanism underlying MCT-1 regulation is largely unknown. We find that MCT-1 is phosphorylated and up-regulated by extracellular signal-regulated kinase (ERK). Furthermore, by using a small inhibitory molecule targeting ERK, we interrupted MCT-1 phosphorylation and stability. Significantly, cells with distinct levels of MCT-1 protein displayed differential sensitivity to ERK inhibitor-induced apoptosis. Treatment with the ERK inhibitor showed marked in vivo antitumor activity in a human DLBCL xenograft model. Our findings establish a functional molecular interaction between MCT-1 and the MEK/ERK signaling pathway and suggest that the activation of MCT-1 function by its upstream kinase ERK plays an important role in lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789340      PMCID: PMC2839501          DOI: 10.1158/0008-5472.CAN-09-1606

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Authors:  Kojo S J Elenitoba-Johnson; Stephen D Jenson; Robert T Abbott; Robert A Palais; Sandra D Bohling; Zhaosheng Lin; Sheryl Tripp; Paul J Shami; Lai Y Wang; Robert W Coupland; Rena Buckstein; Bayardo Perez-Ordonez; Sherrie L Perkins; Ian D Dube; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

2.  Targeted suppression of MCT-1 attenuates the malignant phenotype through a translational mechanism.

Authors:  Krystyna Mazan-Mamczarz; Patrick Hagner; Bojie Dai; Sharon Corl; Zhenqui Liu; Ron B Gartenhaus
Journal:  Leuk Res       Date:  2008-09-27       Impact factor: 3.156

3.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap.

Authors:  A Lazaris-Karatzas; K S Montine; N Sonenberg
Journal:  Nature       Date:  1990-06-07       Impact factor: 49.962

4.  MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival.

Authors:  Bei Zheng; Paolo Fiumara; Yang V Li; Georgios Georgakis; Virginia Snell; Mamoun Younes; Jean Nicolas Vauthey; Antonino Carbone; Anas Younes
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

5.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas.

Authors:  S J Horning; S A Rosenberg
Journal:  N Engl J Med       Date:  1984-12-06       Impact factor: 91.245

6.  Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.

Authors:  Yun Dai; Terry H Landowski; Steven T Rosen; Paul Dent; Steven Grant
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 7.  Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

Authors:  C W Reuter; M A Morgan; L Bergmann
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

8.  The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis.

Authors:  Davide Ruggero; Lorenzo Montanaro; Li Ma; Wei Xu; Paola Londei; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nat Med       Date:  2004-04-18       Impact factor: 53.440

9.  Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

Authors:  Ali R Jazirehi; Mario I Vega; Devasis Chatterjee; Lee Goodglick; Benjamin Bonavida
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

10.  Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies.

Authors:  Bo Shi; Hsin-Ling Hsu; Andy M Evens; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

View more
  19 in total

1.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Authors:  Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

2.  Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

Authors:  Thomas E Witzig; Hui Tang; Ivana N M Micallef; Stephen M Ansell; Brian K Link; David J Inwards; Luis F Porrata; Patrick B Johnston; Joseph P Colgan; Svetomir N Markovic; Grzegorz S Nowakowski; Carrie A Thompson; Cristine Allmer; Matthew J Maurer; Mamta Gupta; George Weiner; Ray Hohl; Paul J Kurtin; Husheng Ding; David Loegering; Paula Schneider; Kevin Peterson; Thomas M Habermann; Scott H Kaufmann
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

3.  MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.

Authors:  Christof Schneider; Manu Setty; Antony B Holmes; Roy L Maute; Christina S Leslie; Lara Mussolin; Angelo Rosolen; Riccardo Dalla-Favera; Katia Basso
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

4.  ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes.

Authors:  Krystyna Mazan-Mamczarz; Patrick R Hagner; Yongqing Zhang; Bojie Dai; Elin Lehrmann; Kevin G Becker; Jack D Keene; Myriam Gorospe; Zhenqui Liu; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-01-05       Impact factor: 22.113

Review 5.  Novel disease targets and management approaches for diffuse large B-cell lymphoma.

Authors:  Wyndham H Wilson; Francisco J Hernandez-Ilizaliturri; Kieron Dunleavy; Richard F Little; Owen A O'Connor
Journal:  Leuk Lymphoma       Date:  2010-08

6.  Activities of Ligatin and MCT-1/DENR in eukaryotic translation initiation and ribosomal recycling.

Authors:  Maxim A Skabkin; Olga V Skabkina; Vidya Dhote; Anton A Komar; Christopher U T Hellen; Tatyana V Pestova
Journal:  Genes Dev       Date:  2010-08-15       Impact factor: 11.361

7.  The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.

Authors:  Dashnamoorthy Ravi; Savita Bhalla; Ronald B Gartenhaus; Jennifer Crombie; Irawati Kandela; Jaya Sharma; Andrew Mazar; Andrew M Evens
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

Review 8.  Targeting the translational machinery as a novel treatment strategy for hematologic malignancies.

Authors:  Patrick R Hagner; Abraham Schneider; Ronald B Gartenhaus
Journal:  Blood       Date:  2010-01-14       Impact factor: 22.113

9.  Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.

Authors:  Sarice R Boston; Rahul Deshmukh; Scott Strome; U Deva Priyakumar; Alexander D MacKerell; Paul Shapiro
Journal:  BMC Cancer       Date:  2011-01-10       Impact factor: 4.430

10.  miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin's lymphoma: novel targets with impact on ERK signaling and cell migration.

Authors:  Min Yue Zhang; Lu Qian Wang; Chor Sang Chim
Journal:  Cell Commun Signal       Date:  2021-05-27       Impact factor: 7.525

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.